In 2019, the situation was that, due to the tax advantages offered in states like Pernambuco, Goiás and Minas Gerais, companies were leaving RJ and SP, and going to these states. At the time, the more than 110 companies associated with Sinfar-RJ fell to just 49. Rio de Janeiro, at this time, represented the most expensive state for pharmaceutical production, with its ICMS at 20%.
By 2019, the situation was that certain states like Pernambuco, Goiás, and Minas Gerais were attracting companies due to their tax incentives, causing many firms based in RJ and SP to move there. As a result, Sinfar-RJ's membership dropped from over 110 to just 49. Rio de Janeiro became the most expensive state for pharmaceutical manufacturing at that time, with its ICMS rate standing at 20%.